with sulphonylureas or insulin compared with conventional treatment andrisk of complications in subjects with type 2 diabetes (UKPDS 33). Lancet352:837 –853 6.Arner P, Pollace T, Lithell H 1991 Different etiologies of type 2 (non-insulin dependent) diabetes mellitus in obese and non obese subjects. Diabetologia34:483 –487 7.Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, UKPDS Study Group 2002 Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study(UKPDS 57). Diabetes Care 25:330 –336 8.Diabetes Prevention Program Research Group 2002 Reduction in the inci- dence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med346:393 –403 9.Frias JP, Yu JG, Kruszynska YT, Olefsky JM 2000 Metabolic effects of tro- glitazone therapy in type 2 diabetic, obese, and lean normal subjects. DiabetesCare 23:64 –69 10.Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa